Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protective Effects of Estradiol on Disease Progression in a Murine Model of Fuchs Endothelial Corneal Dystrophy.

Investigative ophthalmology & visual science·2026
Same author

Advancements and Innovations in Keratoconus Management: A Review of Current Practices.

Journal of clinical medicine·2025
Same author

Stable coexistence and phenol-degradation expression of Cupriavidus sp. strain P-10 and Comamonas thiooxydans strain R2 in phenol-competitive chemostat culture.

Applied microbiology and biotechnology·2025
Same author

In Situ Ionically Cross-Linkable Benzaldehyde-Modified Alginate and Its Bilayer Structure as a Tissue Sealant for Dural Closure.

Biomacromolecules·2025
Same author

Generation of a Mouse Model of Fuchs Endothelial Corneal Dystrophy by Knock-in of CTG Trinucleotide Repeat Expansion in the TCF4 Gene.

Investigative ophthalmology & visual science·2025
Same author

Therapeutic Potential of Emricasan, a Pan-Caspase Inhibitor, in Reducing Cell Death and Extracellular Matrix Accumulation in Fuchs Endothelial Corneal Dystrophy.

Cells·2025

Related Experiment Video

Updated: May 15, 2025

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1
12:36

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1

Published on: July 22, 2022

4.5K

Heterozygous Tcf4 Deficiency Mitigates Fuchs Endothelial Corneal Dystrophy Progression in a Mouse Model.

Suguru Ito1, Yuki Oyama1,2,3, Taichi Yuasa1

  • 1Department of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan.

Investigative Ophthalmology & Visual Science
|April 8, 2025
PubMed
Summary

Heterozygous knockout of Tcf4 (Transcription Factor 4) significantly reduced Fuchs endothelial corneal dystrophy (FECD) progression in mice. This suggests TCF4 is a potential therapeutic target for treating FECD.

More Related Videos

Application of Optical Coherence Tomography to a Mouse Model of Retinopathy
08:22

Application of Optical Coherence Tomography to a Mouse Model of Retinopathy

Published on: January 12, 2022

3.8K
Mouse Eye Enucleation for Remote High-throughput Phenotyping
05:30

Mouse Eye Enucleation for Remote High-throughput Phenotyping

Published on: November 19, 2011

20.2K

Related Experiment Videos

Last Updated: May 15, 2025

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1
12:36

A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1

Published on: July 22, 2022

4.5K
Application of Optical Coherence Tomography to a Mouse Model of Retinopathy
08:22

Application of Optical Coherence Tomography to a Mouse Model of Retinopathy

Published on: January 12, 2022

3.8K
Mouse Eye Enucleation for Remote High-throughput Phenotyping
05:30

Mouse Eye Enucleation for Remote High-throughput Phenotyping

Published on: November 19, 2011

20.2K

Area of Science:

  • Ophthalmology
  • Genetics
  • Molecular Biology

Background:

  • Fuchs endothelial corneal dystrophy (FECD) is a progressive eye disease affecting the cornea.
  • The Q455K mutation in collagen type VIII alpha 2 (Col8a2) is a known genetic cause of FECD.
  • Transcription Factor 4 (Tcf4) plays a role in corneal endothelial cell development and function.

Purpose of the Study:

  • To investigate the therapeutic potential of heterozygous knockout of Tcf4 in ameliorating FECD progression.
  • To utilize the Col8a2Q455K/Q455K mouse model, an established model for FECD, for this study.

Main Methods:

  • Generated Tcf4 heterozygous knockout mice using CRISPR/Cas9.
  • Crossed Tcf4 knockout mice with Col8a2Q455K/Q455K mice to create Col8a2Q455K/Q455K/Tcf4± mice.
  • Analyzed gene expression, guttae formation, corneal endothelial cell density, and extracellular matrix component expression.

Main Results:

  • RNA-Seq revealed differential gene expression, enriched in ion channel pathways and downregulated TNF-associated signaling.
  • Col8a2Q455K/Tcf4± mice showed significantly reduced guttae formation (0.71% vs. 1.87%) and higher corneal endothelial cell density (1819 vs. 1521 cells/mm²).
  • Expression of ECM components, including fibronectin and collagen type I, was decreased in Col8a2Q455K/Tcf4± mice.

Conclusions:

  • Heterozygous knockout of Tcf4 significantly suppressed FECD progression in the mouse model.
  • Reduced guttae formation and preserved corneal endothelial cell density were observed.
  • TCF4 represents a promising therapeutic target for FECD treatment.